{"id":391240,"date":"2015-11-20T00:00:00","date_gmt":"2015-11-20T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/nmrdon0415-biopharma-small-cell-lung-cancer-niche-and-rare-pharmacor-g7-2015\/"},"modified":"2026-03-31T09:02:52","modified_gmt":"2026-03-31T09:02:52","slug":"nmrdon0415-biopharma-small-cell-lung-cancer-niche-and-rare-pharmacor-g7-2015","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/nmrdon0415-biopharma-small-cell-lung-cancer-niche-and-rare-pharmacor-g7-2015\/","title":{"rendered":"Small-Cell Lung Cancer | Niche and Rare Pharmacor | G7 | 2015"},"content":{"rendered":"<p>Small cell lung cancer (SCLC) accounts for approximately 15% of all lung cancer cases and is particularly aggressive with a 5 year survival rate of just 5-10%. Historically, drug development in this indication has been largely unsuccessful, meaning drug treatment options are limited and the use of platinum-based therapy has remained the cornerstone of therapy for many years. SCLC treatment is yet to benefit from the emergence of targeted therapies and biomarker-associated treatments used in other oncology indications. Immune checkpoint inhibitors are now in Phase III clinical development for SCLC; these novel therapies hold promise of fulfilling the high unmet need for more effective therapies in this difficult-to-treat indication.<\/p>\n","protected":false},"template":"","class_list":["post-391240","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-small-cell-lung-cancer","biopharma-date-717"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391240","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391240\/revisions"}],"predecessor-version":[{"id":394363,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391240\/revisions\/394363"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=391240"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}